Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Active, not recruiting · NCT05904691 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 | 2026-05-01 | NCT05904691 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ocugenix Corporation | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Raj K. Maturi, M.D., P.C. | Carmel | United States | 1 |
| Retina Research Institute of Texas | Abilene | United States | 17 |
| Strategic Clinical Research Group LLC | Willow Park | United States | 1 |